18 Years to 85 Years

Patients with ischemic stroke, (that is, stroke that results from a blockage of blood flow to part of the brain), which is accompanied by language dysfunction (e.g. inability to understand speech), visual field defect or inattention to one side of the body or the space around the patient

Patients in whom the study treatment can start no less than 1 and not more than 9 hours after the stroke's onset

Patients with moderate-severe degree of neurological deficit in the 9 hours after stroke onset (defined as NIHSS score of 7 to 20)

Patients that can understand the requirements of the study and are willing to provide written informed consent (If the subject is incapacitated, informed consent will be sought from a legally acceptable representative.)

Patients with a brain (intracerebral or subarachnoid) hemorrhage per screening computed tomography scan

candidates for thrombolytic therapy for the current stroke

patients having a mental impairment that renders them incapable to understand the study's requirements

patients with other diseases that in the investigator's opinion may lead, independently of the current stroke, to further deterioration in the subject's neurological status during the trial period, or may confuse the evaluation of the present stroke

Patients likely to undergo a procedure involving cardiopulmonary bypass during the study period

Patients with medical conditions that may not enable them to complete the study (e.g life-threatening diseases,)

Patients whose condition improves already during the screening period

Patients who already have functional limitations before the present study (retrospective Modified Rankin Scale score of >3)

Patients who suffered a stroke within the past 90 days that seems to have been in the same brain region as the current acute stroke

Patients with severe hypertension (systolic BP >210 mm Hg or diastolic BP >120 mm Hg) or hypotension (systolic BP <90 mm Hg),

Patients with significant history of renal or liver disease(s) (serum creatinine of > 2.0 mg/dL, alanine aminotransferase, aspartate aminotransferase, or gamma-glutamyl transferase values of > threefold the upper normal limit)

Patients with a platelet count of <100,000/mm3

Female patients of childbearing potential who are not using adequate and effective birth control measures or who are pregnant or lactating (the screening evaluation of female subjects of childbearing potential will include a serum pregnancy test.)

Patients who are users of addictive agents, or alcoholics

Patients who have received an investigational drug within the 90 days before the present stroke or such that are past recipients of DP-b99

Age

Diagnosis

Ischemic stroke

Disorder of language

Visual field defect

Hemi-inattention

Onset

NIH-SS

Neurologic deficit

Informed Consent

Compliance

Brain hemorrhage

Therapeutic procedure

Medication

Mental impairment disorders

Cardiopulmonary bypass operation

Life expectancy

Rankin score

Hypertensive disease

Hypotension

Creatinine

GPT (Serum)

GOT (Serum)

Gamma Glutamyl Transpeptidase Measurement

Platelet count - finding

pregnant

Breast feeding, Nursing

Contraception

Alcohol abuse

Drug abuse

Enrollment